Abstract
Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have been linked to several familial and sporadic late-onset cases of Parkinson’s disease. The cumulative data for the effects of mutant forms of this enzyme on neuronal degradation and the pathophysiology of Parkinson’s disease create a compelling case for drug discovery based on inhibition of the mutant forms of LRRK2. This review focuses on structure-activity relationships for inhibitors of LRRK2 and the data supporting a potential role of these agents in treating Parkinson’s disease.
Keywords: Kinase inhibitors, Leucine-rich repeat kinase 2 (LRRK2), Parkinson’s disease.
Current Topics in Medicinal Chemistry
Title:Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease
Volume: 15 Issue: 10
Author(s): Paul J. Gilligan
Affiliation:
Keywords: Kinase inhibitors, Leucine-rich repeat kinase 2 (LRRK2), Parkinson’s disease.
Abstract: Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have been linked to several familial and sporadic late-onset cases of Parkinson’s disease. The cumulative data for the effects of mutant forms of this enzyme on neuronal degradation and the pathophysiology of Parkinson’s disease create a compelling case for drug discovery based on inhibition of the mutant forms of LRRK2. This review focuses on structure-activity relationships for inhibitors of LRRK2 and the data supporting a potential role of these agents in treating Parkinson’s disease.
Export Options
About this article
Cite this article as:
Gilligan J. Paul, Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease, Current Topics in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/156802661510150328223655
DOI https://dx.doi.org/10.2174/156802661510150328223655 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STAT Signaling and Cell Function
Current Genomics Editorial [Hot Topic: PET – CT AND RADIOTHERAPY (Guest Editors: Diana Salvo, Annibale Versari & Luigi Mansi)]
Current Radiopharmaceuticals The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Pediatric Health Effects of Chronic Exposure to Extremely Low Frequency Electromagnetic Fields
Current Pediatric Reviews Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Telomere Dynamics in Response to Chemotherapy
Current Molecular Medicine An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design An Update on MDMX and Dual MDM2/X Inhibitors
Current Topics in Medicinal Chemistry Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Subject Index To Volume 13
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cognitive Impairment in Systemic Lupus Erythematosus: Prevalence and Clinical Importance
Current Rheumatology Reviews Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets